Clinical Trial 22083

Study Title

Real-World Clinical and Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma treated With Commercial CAR-T Therapy

Summary

To date, little is known about the real-world clinical outcomes or PROs among Relapsed/Refractory Multiple Myeloma patients treated with SOC ide-cel and cilta-cel. This study will address this important gap in knowledge

Objective

Aim 1: Describe real-world clinical outcomes (i.e., treatment response rates, incidence and severity of immune-mediated toxicities, progression-free and overall survival) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 2: Describe real-world PROs (i.e., HRQOL, symptom burden) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 3: Explore differences in clinical outcomes and PROs between RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy